Medical Marijuana, Inc. owns appx. 45.5% of AXIM® Biotechnologies.
AXIM® Biotechnologies is an innovative biotechnology company focusing on the research, development, and production of cannabinoid-based pharmaceuticals and supplements with offices in New York City and The Netherlands. AXIM® Biotechnologies was created in November of 2010 with the goal of creating novel treatments for a number of medical conditions.
AXIM® owns the patent for chewing gum as a delivery method for cannabinoids, which it has developed into two separate products. Cannabidiol (CBD)-only Canchew® gum is marketed as a dietary supplement, legal to purchase wherever CBD hemp oil products are sold. In addition, AXIM® Biotechnologies, Inc. will soon start phase 3 clinical trials for their combination CBD/THC (tetrahydrocannabinol) gum, MedChew™ RX, for the treatment of pain and spasticity associated with multiple sclerosis. Once approved by the European Medicines Agency (EMA), the gum will be offered across the European Union.
AXIM® Biotechnologies is an innovative biotechnology company focusing on the research, development, and production of cannabinoid-based pharmaceuticals and supplements.
More recently, AXIM® Biotechnologies has started trials for a new cannabigerol (CBG) based ointment for the treatment of psoriasis and atopic dermatitis, commonly known as eczema. Their patent pending AX-1602 proprietary ointment will be tested in a placebo controlled study to best judge its efficacy for these two dermatological indications.
In addition to AXIM® Biotechnologies CBD products, AXIM® is also expanding its use of CBG in a new line of oral care products, Oraximax™, and a line of cosmetics, Renecann™. Designed for the daily user, these consumer product brands capitalize on hemp’s mix of phytocannabinoids and nutrients in their proprietary formulas.
As part of their future research and development, AXIM® is working on new extraction methods and delivery techniques for cannabinoids, as well as treatment options for ADHD, irritable bowel syndrome, inflammatory bowel disease, ulcerative colitis, and Crohn’s disease. The company is also interested in further developing the antibacterial properties of CBG and the possible use of cannabinoids for smoking cessation in nicotine addicts.
AXIM® has already brought CanChew® Gum, a CBD infused chewing gum to market, and plans to expand with CBG oral care and skin care products.
AXIM® Biotechnologies believes in setting the standard for cannabinoid bioscience through the discovery and commercialization of new materials and technologies for healthy living. AXIM® Biotechnologies plans to complete construction in 2017 on a new state of the art manufacturing plant near the city of Almere, The Netherlands, that will allow them to take a competitive place in the cannabinoid-based marketplace. With several new drugs in clinical trials and many new products in the pipeline, AXIM® is strongly positioned for growth in cannabinoid-based treatments. The partnership between MJNA and AXIM® is a mutually beneficial one- and is poised to advance knowledge and access to the latest in medical cannabinoid products.
NEWS & PRESS
› Owns the patent for chewing gum as a delivery method for cannabinoids. Read more.
› In clinical trials for MedChewRX for pain and spasticity in multiple sclerosis patients. Read more.
› Proof of concept trials underway for their patent pending AX-1602 proprietary ointment for the treatment of eczema and psoriasis. Read more.
› Proud donor to veterans through the “Adopt-a-Soldier Platoon”. Read more.
Latest AXIM Biotechnologies News
This first in the world, patented cannabinoid-based gum is derived from high-CBD hemp oil. Manufactured in the U.S. and legal in all 50 states, sugar-free mint flavored CanChew® gum is an efficient and reliable method of absorbing CBD hemp oil as a dietary supplement. Each piece of CanChew® contains 50 mg of hemp oil and 10 mg of CBD.
AXIM Biotech is currently in clinical trials for their combined CBD and THC delayed-release gum, MedChew® RX, for the pain and spasticity associated with multiple sclerosis. Once approved by the European Medicines Agency (EMA), the gum will be offered across the European Union.
AXIM Biotechnologies’ patent-pending dental hygiene line, based on Cannabigerol (CBG), will target both daily use oral care and the resolution of oral infections and gum disease. AXIM has selected CBG for its suggested anti-inflammatory and antibacterial properties to protect against the daily trauma caused to the mouth through chewing, speaking, and buildup of infectious organisms.
AXIM’s hemp oil derived rejuvenating skin care line, Renecann™ cannabinoid based hair and skin products will be developed for the discerning daily use customer. Capitalizing on the cannabinoids, essential amino acids, and vitamins and minerals available in hemp oil, the line will contain products like anti-aging cream, lip balm, diaper rash cream, and anti-acne lotion.
AX-1602 is AXIM Biotechnologies’ patent-pending topical ointment for psoriasis and eczema, formulated with cannabigerol (CBG) and other cannabinoids. AXIM’s CBG ointment will be tested in a placebo controlled study to best judge its efficacy before moving into phase I trials.